Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer

European Journal of Dermatology

Volumn 23, Issue 1, 2013, Pages 77-82

  Jo, Jae Cheol ^a   Hong, Yong Sang ^a   Kim, Kyu Pyo ^a   Lee, Jae Lyun ^a   Kim, Hwa Jung ^a   Lee, Mi Woo ^a   Lim, Seok Byung ^a   Yu, Chang Sik ^a   Kim, Jin Cheon ^a   Kim, Jong Hoon ^a   Kim, Tae Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acneiform rash; Cetuximab; Metastatic colorectal cancer; Topical vitamin K1 cream

Indexed keywords

CETUXIMAB; IRINOTECAN; MINOCYCLINE; OXALIPLATIN; PHYTOMENADIONE; RECONVAL K1; UNCLASSIFIED DRUG;

ACNE; ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MORBIDITY; RISK FACTOR;

ACNEIFORM RASH; CETUXIMAB; METASTATIC COLORECTAL CANCER; TOPICAL VITAMIN K1 CREAM;

ACNEIFORM ERUPTIONS; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG ERUPTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SKIN CREAM; TIME FACTORS; TREATMENT FAILURE; VITAMIN K 1; VITAMINS; YOUNG ADULT;

EID: 84875044772     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1899     Document Type: Article

References (25)

1. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-6.
2. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
3. Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22: 524-35.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
5. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.
6. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
7. Woodworth CD, Michael E, Marker D, et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 2005; 4: 650-8.
8. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303-12.
9. Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997; 109: 751-6.
10. Perez-Soler R, Zou Y, Li T, Ling YH. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res 2011; 17: 6766-77.
11. Ocvirk J, Rebersek M. Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. ASCO Meeting Abstracts 2009; 27: e15087.
12. Radovics N, Kornek G, Thalhammer F, et al. Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash. ASCO Meeting Abstracts 2010; 28: e19671.
13. Pinto C, Barone C, Ferrari D, et al. Topical vitamin K1 in the management of skin rash during anti-EGFR monoclonal antibody treatment in patients with metastatic cancer: Italian Observational Study. ASCO Meeting Abstracts 2011; 29: e14068.
14. Tomkova H, Pospikova M, Zabojnikova M, et al. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis. J Eur Acad Dermatol Venereol 2011.
15. Kang MJ, Hong YS, Kim KP, et al. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs 2011.
16. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
17. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006; 11: 1010-7.
18. Ocvirk J, Rebersek M, Boc M, Mesti T, Ebert M. Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2010; 28: e14011.
19. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113: 847-53.
20. Scope A, Agero AL, Dusza SW, et al. Randomized doubleblind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390-6.
21. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-65.
22. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007; 25: 133-5, v.
23. Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulasepositive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010; 15: 1002-8.
24. Balagula Y, Wu S, Su X, Lacouture ME. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann Oncol 2011; 22: 2366-74.
25. Jatoi A, Green EM, Rowland KM, Jr, Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77: 120-3.